Tumor-targeted delivery of biologically active TRAIL protein
Open Access
- 15 January 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Gene Therapy
- Vol. 17 (5), 334-343
- https://doi.org/10.1038/cgt.2009.76
Abstract
The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a potent inducer of tumor cell apoptosis, but concerns of considerable liver toxicity limit its uses in human cancer therapy. Here, we show that i.v. injected Escherichia coli DH5α (E. coli DH5α) specifically replicates in solid tumors and metastases in live animals. E. coli DH5α does not enter tumor cells and suits for being the vector for soluble TRAIL (sTRAIL), which induces apoptosis by activating cell-surface death receptors. With the high ‘tumor-targeting’ nature, we demonstrate that intratumoral (i.t.) and intravenous injection of sTRAIL-expressing E. coli DH5α results in the tumor-targeted release of biologically active molecules, which leads to a dramatic reduction in the tumor growth rate and the prolonged survival of tumor-bearing mice. TRAIL delivery by E. coli DH5α did not cause any detectable toxicity to any organs, suggesting that E. coli DH5α-delivered sTRAIL protein therapy may provide a feasible and effective form of treatment for solid tumors.Keywords
This publication has 46 references indexed in Scilit:
- Tumor-targeting prodrug-activating bacteria for cancer therapyCancer Gene Therapy, 2008
- Potent antitumor effect of TRAIL mediated by a novel adeno‐associated viral vector targeting to telomerase activity for human hepatocellular carcinomaThe Journal of Gene Medicine, 2008
- Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAILCancer Gene Therapy, 2007
- A Capsid-Modified, Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL Leads to Enhanced Cancer Cell Killing in Human Glioblastoma ModelsCancer Research, 2007
- Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancerProceedings of the National Academy of Sciences of the United States of America, 2007
- Adeno‐associated virus‐mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor modelThe Journal of Gene Medicine, 2005
- Systemic Administration of an Attenuated, Tumor-TargetingSalmonella typhimuriumto Dogs with Spontaneous Neoplasia: Phase I EvaluationClinical Cancer Research, 2005
- Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patientsCancer Gene Therapy, 2003
- Monitoring BioluminescentStaphylococcus aureusInfections in Living Mice Using a NovelluxABCDEConstructInfection and Immunity, 2000
- Safety and antitumor activity of recombinant soluble Apo2 ligandJCI Insight, 1999